Startup aims to upend diabetes care with matchstick-size implant
Intarcia Therapeutics Inc. is betting its matchstick-size pump could take market share from Eli Lilly and Co., AstraZeneca Plc and Novo Nordisk A/S.
Diabetes
Articles
Lilly to launch Lantus biosimilar in Europe in third quarter
Indianapolis-based Eli Lilly and Co. plans to introduce its version of Sanofi’s Lantus insulin for diabetes in Europe in the third quarter, said Enrique Conterno, the president of Lilly Diabetes.
Sponsorship of diabetic NASCAR driver may help Lilly regain market share
21-year-old Ryan Reed stunned racing gurus on Feb. 21 by winning his first NASCAR race on stock-car racing’s most hallowed grounds. He did it with a wireless device attached to his stomach feeding a constant stream of data to a dashboard-mounted glucose monitor.
Lilly to introduce Lantus copy in Europe after patent expires
Paris-based drugmaker Sanofi had revenue of $8.4 billion from Lantus last year. It lost U.S. patent protection this month and will lose exclusive rights in Europe in May.
Lilly to delay U.S., EU approval of basal insulin
Although the experimental diabetes drug is in final-stage testing and showing promising results, Lilly wants to better understand its effect on liver fat.
Revenue has nearly tripled in past two years for blood-test maker
PTS Diagnostics engineered an about-face on its business plan five years ago, ditching its retail strategy to focus on serving physicians and nurse practitioners. This year, PTS is on pace to record revenue of nearly $50 million, up from $17 million two years ago.
LDI acquisition could be latest springboard for growth
Indianapolis-based private investment company LDI Ltd. has acquired a small biotech manufacturer in a deal it says could be the launching point for many more acquisitions.
FDA approves Eli Lilly’s injectable diabetes drug
The agency on Thursday cleared the drug, Trulicity, as a weekly injection to improve blood sugar control in patients with type 2 diabetes, which affects more than 26 million Americans.
Recent wins worth $4B to Lilly market value
Lilly is finally putting meat on the bones of its predictions about its experimental diabetes and cancer drugs. That gives investors the certainty they crave that Lilly’s future revenue won’t remain in its 2014 doldrums.
FDA approves Lilly, Boehringer diabetes drug
The Food and Drug Administration said Friday it will permit Jardiance tablets to be used by adult patients with type 2 diabetes who also are trying to control their condition with diet and exercise.
Lilly wins EU backing for version of insulin drug
Lantus, which garnered $7.8 billion in sales for Paris-based Sanofi in 2013, loses patent protection in Europe in May next year.
Would-be Lilly foe wins U.S. panel backing for inhaled insulin
Advisers to the Food and Drug Administration voted 13-1 and 14-0 that the drug, Afrezza, should be approved for Type 1 and Type 2 diabetes, respectively. The FDA doesn’t have to follow the panel’s recommendation.
Lilly diabetes drug wins backing from EU regulator
Indianapolis-based Lilly is expected to garner $518 million in annual sales from Jardiance by 2019, according to the average of five analyst estimates compiled by Bloomberg.
Lilly diabetes drug rejected by FDA over manufacturing issue
The Lilly-Boehringer drug empagliflozin is projected to reach sales of $295 million for Lilly in 2019, but it won’t be able to sell it until issues are resolved at a German plant.
Lilly diabetes drug matches competitors’ effectiveness
The Indianapolis drugmaker said dulaglutide performed as well as Victoza, a best-selling drug for Type 2 diabetics made by Denmark-based Novo Nordisk. Analysts think dulaglutide could reach annual sales of $1.5 billion.
Falling reimbursements force Roche to innovate
U.S. sales are plunging for Roche Diagnostics Corp. and its fellow makers of diabetes-care devices because of lower reimbursements from the federal Medicare program. In five years, two of the four largest companies will have sold or closed their diabetes businesses, according to two industry analysts.
Lilly to spend another $700M in growing market for diabetes products
The move includes a $45 million investment for Lilly's operations in Indianapolis, on top of $400 million in investments the company announced over the past two years.
Investors brace for lean years from Lilly
In a new round of predictions this month, Wall Street analysts indicated they expect Eli Lilly and Co.’s revenue to fall next year and to remain below 2013 levels until 2020.
Lilly bets quality over quantity will pay off in diabetes battle
Eli Lilly and Co. is counting on the quality of a diversified product portfolio over boosting its sales forces to grab a bigger slice of the $22 billion U.S. diabetes market, a difference in strategy to some of its rivals.
Drugmakers turn up marketing efforts in diabetes market
With a half-dozen new products lined up for approval within two years, the fight to win the growing $22 billion U.S. diabetes market is expected to intensify.